Moreover, we show that combinatorial treatment with the MEK inhibitor Selumetinib and the FAK inhibitor Defactinib fully abrogates their transforming ability, opening new therapeutic opportunities for plexiform neurofibroma treatment. The gene discussed is PTK2; the disease is plexiform neurofibroma.